Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Aom0319 in Healthy White Subjects
NCT05555758Phase 1Completed
- Sponsor
- Amckaus PTY LTD
- Start
- Dec 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in neuromuscular blockade (NMB) comparing Adamgammadex Sodium (Aom0319) with Placebo (2 arms). Primary endpoint: Number, severity and type of adverse events at 8 days. Started Dec 2022; status: completed.
02
Drugs
adamgammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT05555758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05555758.